Moderna, Merck Find 42% Lower Melanoma Recurrence-or-Death Risk

Estimated two-year recurrence-free survival was 82.2% with the combination and 70.0% with Keytruda alone; overall-survival data remain immature.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.